Clinical Trial Update: Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing different administration schedules of ABI-007 (Abraxane) with Bevacizumab in metastatic breast cancer; study terminated with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• ABI-007 (Abraxane) (paclitaxel protein-bound particles for injectable suspension)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Celgene | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Status: TERMINATED | Results posted: 2012-03-13